In our studies, targeting the SPHK1/S1PR3 axis with inhibitors reduced the expression of SPHK1 and S1PR3 and the biosynthesis of S1P (data now shown), significantly suppressed TSC2-deficient cells metastasis and prolonged the survival of mice carrying xenograft tumor (Fig. 7). Here, S1PR3 is linked to neoplasm.